Unknown

Dataset Information

0

Aberrant BAF57 signaling facilitates prometastatic phenotypes.


ABSTRACT: BAF57, a component of the switching-defective and sucrose nonfermenting (SWI/SNF) chromatin-remodeling complex conglomerate, modulates androgen receptor activity to promote prostate cancer. However, the molecular consequences of tumor-associated BAF57 expression have remained undefined in advanced disease such as castration-resistant prostate cancer and/or metastasis.Clinical human specimens of primary and metastatic prostate cancer were immunohistochemically examined for tumor-grade association of BAF57 expression. Global gene expression analyses were conducted in models mimicking tumor-associated BAF57 expression. Aberrant BAF57-dependent gene expression changes, bypass of androgen-mediated signaling, and chromatin-specific SWI/SNF complex alterations with respect to cytoskeletal remodelers such as integrins were validated. Cell migration assays were used to profile the biologic phenotypes conferred under conditions simulating tumor-derived BAF57 expression.Immunohistochemical quantitation of primary human specimens revealed that BAF57 was significantly and aberrantly elevated as a function of tumor grade. Critically, gene expression analyses showed that BAF57 deregulation circumvented androgen-mediated signaling, elicited ?2 integrin upregulation, and altered other SWI/SNF complex components at the ?2 integrin locus. BAF57-dependent ?2 integrin induction conferred a prometastatic migratory advantage, which was attenuated by anti-?2 integrin antibody blockade. Furthermore, BAF57 was found to be markedly upregulated in human prostate cancer metastases of the lung, lymph node, and dura.The findings herein, identifying tumor-associated BAF57 perturbation as a means to bypass androgen-signaling events that facilitate novel prometastatic phenotypes, link BAF57 upregulation to tumor dissemination. These data thereby establish BAF57 as a putative marker of metastatic potential that could be leveraged for therapeutic intervention.

SUBMITTER: Balasubramaniam S 

PROVIDER: S-EPMC3655134 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Aberrant BAF57 signaling facilitates prometastatic phenotypes.

Balasubramaniam Sucharitha S   Comstock Clay E S CE   Ertel Adam A   Jeong Kwang Won KW   Stallcup Michael R MR   Addya Sankar S   McCue Peter A PA   Ostrander William F WF   Augello Michael A MA   Knudsen Karen E KE  

Clinical cancer research : an official journal of the American Association for Cancer Research 20130314 10


<h4>Purpose</h4>BAF57, a component of the switching-defective and sucrose nonfermenting (SWI/SNF) chromatin-remodeling complex conglomerate, modulates androgen receptor activity to promote prostate cancer. However, the molecular consequences of tumor-associated BAF57 expression have remained undefined in advanced disease such as castration-resistant prostate cancer and/or metastasis.<h4>Experimental design</h4>Clinical human specimens of primary and metastatic prostate cancer were immunohistoche  ...[more]

Similar Datasets

2013-06-04 | E-GEOD-44418 | biostudies-arrayexpress
2013-06-04 | GSE44418 | GEO
| S-EPMC3556393 | biostudies-literature
| S-EPMC5409794 | biostudies-literature
| S-EPMC6783548 | biostudies-literature
| S-EPMC3284390 | biostudies-literature
| PRJEB82597 | ENA
| S-EPMC2860937 | biostudies-other
| S-EPMC3759196 | biostudies-literature
| S-EPMC2701211 | biostudies-literature